The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
CAR T cells produced in vivo to treat cardiac injury
Open accessAbstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 601–700 of 1,001
Bajbouj, K., Xiao, Z., Todd, L., Huang, L., Papp, T. E., Halilovic, F., Ramani, J., Bao, Y., Butcher, M., Bot, A., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0663 · Cited by 19
Self-citationIn vivo CAR-cell therapy: current challenges and emerging therapeutic advances
Yang, Y.-M., Bao, B., Cao, Y.-H., Yao, J., Ding, Y.-F., Hu, Y.-Y., Fan, F., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00447-y · Cited by 16
A guide to CAR T cell therapies: development, current status and future prospects
Rafei, H., Upadhyay, R., & Sharma, P. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01322-1 · Cited by 16
Terapia génica para la insuficiencia cardiaca y las miocardiopatías
Argirò, A., Ding, J., & ADLER, E. D. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.06.016 · Cited by 13
Eş, İ., Thakur, A., Khaneghah, A. M., Foged, C., & de la Torre, L. G. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108342 · Cited by 15
Ferroptosis in diabetic cardiomyopathy: Advances in cardiac fibroblast-cardiomyocyte interactions
Wang, M., Mo, D.-G., Zhang, N., & Yu, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35219 · Cited by 15
Comprehensive macro and micro views on immune cells in ischemic heart disease
Zhao, Y., Tan, M., Yin, Y., Zhang, J., Song, Y., Li, H., Lin, Y., Jin, Y., Wu, Z., Yang, T., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13725 · Cited by 15
Bottom-up synthetic immunology
Göpfrich, K., Platten, M., Frischknecht, F., & Fackler, O. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01744-9 · Cited by 14
Strategies for Organ‐Targeted mRNA Delivery by Lipid Nanoparticles
Liao, H., Liao, J. P., Zeng, L., Cao, X., Fan, H., & Chen, J. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2004 · Cited by 17
The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes
Tarab‐Ravski, D., Stotsky‐Oterin, L., Elisha, A., Kundoor, G. R., Ramishetti, S., Hazan‐Halevy, I., Haas, H., & Peer, D. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.014 · Cited by 13
Gharatape, A., Amanzadi, B., Mohamadi, F., Rafieian, M., & Majidi, R. F. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2416377 · Cited by 14
CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad
Baena, J. C., Pérez, L. M., Toro-Pedroza, A., Kitawaki, T., & Loukanov, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313157 · Cited by 15
Caël, B., Bôle‐Richard, E., Garnache‐Ottou, F., & Aubin, F. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.12.1066 · Cited by 15
Ojansivu, M., Barriga, H. M. G., Holme, M. N., Morf, S., Doutch, J., Andaloussi, S. E., Kjellman, T., Johnsson, M., Barauskas, J., & Stevens, M. M. (2025) · Advanced Materials · doi:10.1002/adma.202419538 · Cited by 15
Cardiac Fibroblasts: Helping or Hurting
Shameem, M., Olson, S. L., de Velasco, E. M. F., Kumar, A., & Singh, B. N. (2025) · Genes · doi:10.3390/genes16040381 · Cited by 16
Zhao, Y., Su, X., Xiang, B., Zhang, S., & Zhou, X. (2025) · MedComm · doi:10.1002/mco2.70198 · Cited by 13
The next innovations in chimeric antigen receptor T cell immunotherapies for cancer
Anupindi, K., Malachowski, J., Hodson, I., Zhu, D., June, C. H., & Levine, B. L. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.05.010 · Cited by 13
Self-citationRurik, J. G., & Epstein, J. A. (2022) · DNA and Cell Biology · doi:10.1089/dna.2022.0171 · Cited by 13
Self-citationYe, B., Hu, Y., ZHANG, M., & Huang, H. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0047 · Cited by 20
T-cell Immunotherapy and Cardiovascular Disease
Stein-Merlob, A. F., Ganatra, S., & Yang, E. H. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.008 · Cited by 13
Cardiovascular disease and chimeric antigen receptor cellular therapy
Rao, A., Stewart, A. F., Eljalby, M., Ramakrishnan, P., Anderson, L. D., Awan, F. T., Chandra, A., Vallabhaneni, S., Zhang, K., & Zaha, V. G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.932347 · Cited by 13
Defining cardiac fibrosis complexity and regulation towards therapeutic development
Claridge, B., Drack, A., Pinto, A. R., & Greening, D. W. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.163 · Cited by 16
Phan, H. T. L., Kim, K., Lee, H., & Seong, J. K. (2023) · Genes · doi:10.3390/genes14020483 · Cited by 17
Learmonth, M., Corker, A., Dasgupta, S., & DeLeon‐Pennell, K. Y. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00250.2023 · Cited by 13
Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect
Majid, A., Hassan, F. O., Hoque, M. M., Gbadegoye, J. O., & Lebeche, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070313 · Cited by 16
Sun, M., Li, W., & Chen, W. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2251839 · Cited by 14
The role of cardiac microenvironment in cardiovascular diseases: implications for therapy
Yao, J., Chen, Y., Huang, Y., Sun, X., & Shi, X. (2024) · Human Cell · doi:10.1007/s13577-024-01052-3 · Cited by 14
Recent advances and future prospects in direct cardiac reprogramming
Xie, Y., Handel, B. V., Li, Q., & Ardehali, R. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00377-w · Cited by 12
Myeloid Cell‐Triggered In Situ Cell Engineering for Robust Vaccine‐Based Cancer Treatment
Li, W., Su, J., Zhang, B., Zhao, L., Zhuo, S., Wang, T., Hu, H., & Li, Y. (2024) · Advanced Materials · doi:10.1002/adma.202308155 · Cited by 12
Potential Application of Modified mRNA in Cardiac Regeneration
Wang, A. Y. L., Chang, Y., Chen, K., & Loh, C. Y. Y. (2024) · Cell Transplantation · doi:10.1177/09636897241248956 · Cited by 13
Metabolism and bioenergetics in the pathophysiology of organ fibrosis
Miguel, V., Alcalde‐Estévez, E., Sirera, B., Rodríguez‐Pascual, F., & Lamas, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.001 · Cited by 13
Therapeutic applications of cell engineering using mRNA technology
He, Y., Johnston, A. P. R., & Pouton, C. W. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.012 · Cited by 14
Nanoparticle-mediated universal CAR-T therapy
Fan, M., Zheng, J., Huang, Y., Lu, M., Shang, Z., & Du, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124779 · Cited by 13
Li, S., Tao, B., Wan, J., Montecino‐Rodriguez, E., Wang, P., Ma, F., Sun, B., Gu, Y., Ramadoss, S., Su, L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101795 · Cited by 13
Advances in RNA therapy for the treatment of autoimmune diseases
Zhang, Y., Zang, C., Mao, M., Zhang, M., Tang, Z., Chen, W., & Wu, Z. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103753 · Cited by 14
The application of glycosylated liposomes in targeted drug delivery
Wen, J., Xu, J., Hong, M. H., Li, J., & Li, T. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106638 · Cited by 14
Liang, Z., Xie, H., & Wu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1520063 · Cited by 12
Qin, Y., Li, M., & Liu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1514335 · Cited by 12
Xue, L., Zhang, C., Yin, Q., Bai, Y., Li, J., & Qiu, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113737 · Cited by 12
Zhu, L., Liu, J., Li, J., Wang, N., Yan, Z., & Su, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1514994 · Cited by 15
Anitha, K., Chenchula, S., Vardhan, K. V., Padmavathi, R., Varshini, T. S., Amerneni, L. S., Amerneni, K. C., & Chavan, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02923-x · Cited by 14
Meng, S., Hara, T., Sato, T., Tatekawa, S., Arao, Y., Saito, Y., Hirai, T., Motooka, D., Rennie, S., Satoh, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-31128-5 · Cited by 16
Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy
Wang, R., Yu, J., Caligiuri, M. A., & Ma, S. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3748 · Cited by 17
Lipid nanoparticle–mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy
Yin, Q., Liang, X., Zhang, C., Bai, Y., Li, J., Qian, F., & Qiu, M. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509698123 · Cited by 16
Zou, C., Hu, J., Lu, D., Li, Q., Jiang, Y., Wang, R., Wang, H., Lei, X., Li‐Ling, J., Yang, H., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.006 · Cited by 15
Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies
Michaels, Y. S., Durland, L. J., & Zandstra, P. W. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0008 · Cited by 13
Role of angiogenic transdifferentiation in vascular recovery
Cooke, J. P., & Lai, L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1155835 · Cited by 12
Lu, R., Liang, K.-H., Chiang, H.-L., Hsu, F., Lin, H.-T., Chen, W.-Y., Ke, F.-Y., Kumari, M., Chou, Y., Tao, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15587 · Cited by 12
TNC‑targeted CAR‑macrophage therapy alleviates liver fibrosis in mice
Chen, K., Lin, Z., Chen, L., Zhou, Y., Zhang, W., Wan, H., Huo, Y., Fu, Q., Gao, Z., Cheng, H., et al. (2025) · Military Medical Research · doi:10.1186/s40779-025-00667-3 · Cited by 11
“Given the remarkable efficacy of CAR-T cell therapy in hematological cancers, this technology has been extended to treat various diseases, including solid tumors, aging, and fibrotic disorders [40, 41].”
Pharmaceutical strategies for optimized mRNA expression
Shi, Y., Mao, J., Wang, S., Ma, S., Luo, L., & You, J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122853 · Cited by 11
Wu, Y., Li, M., Zhan, S., Li, M., Huang, J., Chen, X., Chen, L., Gao, X., Chen, H., Chen, H., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06244-5 · Cited by 12
Antibody targeted delivery of lipid nanoparticles for RNA therapeutics to immune cells
Kiaie, S. H., Salehi‐Shadkami, H., Sajadi, S. M. S., Gharehchelou, B., & Zangi, A. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145854 · Cited by 14
Engineering Hybrid Extracellular Vesicles for Functional mRNA Delivery
Louro, A. F., Gomes, I., Lu, C., Alfonzo‐Méndez, M. A., Dekker, N., Khan, M., & Lázaro‐Ibáñez, E. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509636 · Cited by 14
Ferrand, M., Rocca, C. J., Corre, G., Buffa, V., Frin, S., Garnache‐Ottou, F., Bôle‐Richard, E., Albini, S., Richard, I., & Galy, A. H. M. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101545 · Cited by 11
Wang, K., Yin, Z., Zhang, Y., Wu, X., & Fan, L. (2025) · The FASEB Journal · doi:10.1096/fj.202502269r · Cited by 12
Polten, R., Kutle, I., Stalp, J. L., Hachenberg, J., Seyda, A., Neubert, L., Kamp, J. C., von Kaisenberg, C., Schaudien, D., Hillemanns, P., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2556714 · Cited by 12
Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches
Prazeres, P. H. D. M., da Silva, G. C., Azevedo, G., da Silva, N. J. A., Costa, P. A. C., da Silva, W., Lobo, A. O., & Guimarães, P. P. G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s541061 · Cited by 12
Signal control during tissue regeneration in adult animals
Bangru, S., Diegmiller, R., Talia, S. D., & Poss, K. D. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00917-1 · Cited by 15
O'Brien, E. M., Tylek, T., Geisler, H. C., Mukalel, A. J., Whitaker, R. C., Sung, S., Binder‐Markey, B. I., Weissman, D., Mitchell, M. J., & Spiller, K. L. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123869 · Cited by 12
Self-citationNguyen, D. A. H., & Quang, M. T. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01533-2 · Cited by 13
Novel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics
Zhang, H., Han, S., Zhang, X., Ma, J., Jin, L., Wang, Y., Ma, Y., Ma, T., Yu, F., & Song, G. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505340 · Cited by 19
Next-generation programmable cell therapies for precision medicine
Teixeira, A. P., Aubel, D., & Fussenegger, M. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00945-3 · Cited by 15
Zeng, J., Papp, T. E., Akyianu, A., Bahena, A., Leo, L., Halilovic, F., & Parhiz, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115043 · Cited by 11
Self-citationChien, K. R., Foo, K. S., & Witman, N. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01459-7 · Cited by 17
Soni, S. S., D’Elia, A. M., & Rodell, C. B. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01290-2 · Cited by 11
Welch, M., Flusberg, D. A., Hsi, P. T., Haroutunian, N. J., Santos, J. A. L., Kim, E. S., Markovic, S., Coppeta, J. R., Lissandrello, C. A., Balestrini, J. L., et al. (2023) · Advanced Materials Technologies · doi:10.1002/admt.202300275 · Cited by 11
Synthetic Cell-Based Immunotherapies for Neurologic Diseases
von Baumgarten, L., Stauss, H. J., & Lünemann, J. D. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200139 · Cited by 11
Multimodal probing of T-cell recognition with hexapod heterostructures
Huang, X., Meng, L., Cao, G., Promiński, A., Hu, Y., Yang, C., Chen, M., Shi, J., Gallagher, C., Cao, T., et al. (2024) · Nature Methods · doi:10.1038/s41592-023-02165-7 · Cited by 12
Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies
Dankar, R., Wehbi, J., & Refaat, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040461 · Cited by 11
In vivo gene delivery to immune cells
Siebart, J. C., Chan, C. S., Yao, X., Su, F., & Kwong, G. A. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103169 · Cited by 12
CAR-T cell therapy in rheumatic diseases: a review article
Patil, H., Bharadwaj, R. K., Dutta, N., Ramaswamy, S., Prasad, B. S., & Mamadapur, M. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07451-7 · Cited by 12
Koenig, A. L., Kadyrov, F. F., Amrute, J., Yang, S., Weinheimer, C. J., Nigro, J. M., Kovacs, A., Li, W., Smith, G. B., Yeh, L., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci189684 · Cited by 14
Testa, S., Haabeth, O. A. W., Blake, T. R., Castillo, T. J. D., Czerwinski, D. K., Rajapaksa, R., Wender, P. A., Waymouth, R. M., & Levy, R. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00469 · Cited by 11
Gao, T. A., & Chen, Y. Y. (2022) · Science · doi:10.1126/science.abn0851 · Cited by 11
Functional diversification and dynamics of CAR-T cells in patients with B-ALL
Li, Z., Zhao, L., Zhang, Y., Zhu, L., Mu, W., Ge, T., Jin, J., Tan, J., Cheng, J., Wang, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113263 · Cited by 12
Research advances of nanoparticles for CAR-T therapy in solid tumors
Chen, B., Gong, L., Feng, J. Q., Jin, M., Chen, L., Gao, Z., & Huang, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109432 · Cited by 10
The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseases
Liu, Z., Xiao, Y., Lyu, J., Jing, D., Liu, L., Fu, Y., Niu, W., Jin, L., & Zhang, C. (2023) · Protein & Cell · doi:10.1093/procel/pwad061 · Cited by 10
Targeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 13
CAR T-cells for pediatric solid tumors: where to go from here?
Trautmann, T., Yakobian, N., & Nguyen, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10214-6 · Cited by 12
CAR assembly line: Taking CAR T-cell manufacturing to the next level
Wang, J., & Caimi, P. F. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101595 · Cited by 12
Innovative gene delivery systems for retinal disease therapy
Wu, H., Dong, L., Jin, S., Zhao, Y.-W., & Zhu, L. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00797 · Cited by 10
Zeng, L., Li, Y., Wang, X., Xiao, W., Long, Z., & Sun, L. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103350 · Cited by 10
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Chen, X., Wu, C. F., Tang, F., Zhou, J., Mo, L., Li, Y., & He, J. (2025) · Advanced Science · doi:10.1002/advs.202505067 · Cited by 15
RNA immunotherapy: revolutionizing cancer and autoimmune disease treatments
Savguira, M., Chen, D., Dong, S., & Li, B. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.06.008 · Cited by 15
Pan, T. S., Yang, C.-H., Zhao, K., Sun, Y.-L., Rao, Z., Qu, W., Zhang, S., Jin, X., Yu, Y., & Zhang, X. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100143 · Cited by 10
Hu, X., Ge, C., Huang, C., He, D., Yao, X., Cheng, J., Guo, J., Li, L., Ye, Y., Li, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06866-9 · Cited by 10
Self-citationZhao, H., Gao, Y., Qi, Y., An, Z., Li, M., Chen, J., Ma, S., Song, W., & Chen, X. (2025) · ACS Nano · doi:10.1021/acsnano.5c12386 · Cited by 11
Launspach, M., Macos, J., Afzal, S., Hohmann, J., Appis, M. L., Pilgram, M., Beez, S., Ohlendorf, E., van der Ven, C. F. T., Lachiheb, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67328-w · Cited by 13
An AAV variant enables human T cell engineering in vivo
Lu, Z., Ni, K., Liu, W., Song, Q., Zheng, R., Wei, M., Zhang, Y., Wang, J., Wei, L., Wu, C., et al. (2026) · Vita · doi:10.15302/vita.2026.01.0008 · Cited by 10
Lipid–Polymer Hybrid Nanoparticles (LPHNPs) for RNA Delivery
Saiding, Q., Xiao, F., Khan, M. M., Kong, N., Huang, X., & Tao, W. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00874 · Cited by 15
Frostegård, E., Bobrova, T., Leinebø, A., Leray, T., Ghosh, S., García‐Hevia, L., Puccinelli, C., Riccio, L., Sorani, J., Bonifazi, D., et al. (2026) · Advanced Science · doi:10.1002/advs.202522864 · Cited by 12
Empowering gene delivery with protein engineering platforms
Kizerwetter, M., Pietz, K., Tomasovic, L. M., & Spangler, J. B. (2022) · Gene Therapy · doi:10.1038/s41434-022-00379-6 · Cited by 10
Zfp281 and Zfp148 control CD4 + T cell thymic development and T H 2 functions
Chopp, L. B., Zhu, X., Gao, Y., Nie, J., Singh, J., Kumar, P., Young, K. Z., Patel, S., Li, C., Balmaceno-Criss, M., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adi9066 · Cited by 10
Redirecting Human Conventional and Regulatory T Cells Using Chimeric Antigen Receptors
Zimmerman, C. M., Robino, R. A., Cochrane, R. W., Dominguez, M., & Ferreira, L. M. R. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3593-3_15 · Cited by 10
Expanding the horizon of transient CAR T therapeutics using virus-free technology
Enríquez, L., Attia, N., Gallego, I., Mashal, M., Maldonado, I., Puras, G., & Pedraz, J. L. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108350 · Cited by 11
Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
Li, Y., Hu, Z., Li, Y., & Wu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409021 · Cited by 13
Recent Advancements in Biomaterials for Chimeric Antigen Receptor T Cell Immunotherapy
Yu, G., Ye, Z., Yuan, Y., Wang, X., Li, T., Wang, Y., Wang, Y., & Yan, J. (2024) · Biomaterials Research · doi:10.34133/bmr.0045 · Cited by 11
Guo, S., Qi, X., Zhang, L., Lu, K., Li, X., Zhu, J., & Feng, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114086 · Cited by 11
Chimeric antigen receptor–based therapies beyond cancer
Andrés, M. V., Muñoz‐Sánchez, G., Carrillo‐Serradell, L., Gutiérrez‐Hernández, M. D. M., Català, C., Isamat, M., & Lozano, F. (2023) · European Journal of Immunology · doi:10.1002/eji.202250184 · Cited by 11
Transformative Materials for Interfacial Drug Delivery
Desai, P. B., Dasgupta, A., Sofias, A. M., Peña, Q., Göstl, R., Slabu, I., Schwaneberg, U., Stiehl, T., Wagner, W., Jockenhoevel, S., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301062 · Cited by 10
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.